Clinical Trials Logo

Malignant Pleural Effusion clinical trials

View clinical trials related to Malignant Pleural Effusion.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05330065 Not yet recruiting - Clinical trials for Malignant Pleural Effusion

A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion

Start date: August 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Patients with a variety of malignancies can develop malignant pleural effusion (MPE). MPE can cause significant symptoms and result in a marked decrease in quality of life and a poor prognosis. MPE is primarily considered as an immune and vascular manifestation of pleural metastases. The combined use of anti-angiogenic therapy and immunotherapy may be a promising strategy for MPE. This is a Phase Ib/II clinical trial to evaluate the safety and tolerability of administering bevacizumab and camrelizumab into the intrapleural space of subjects with malignant pleural effusion through a pleurX catheter.

NCT ID: NCT04985357 Not yet recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs

Start date: June 2024
Phase:
Study type: Observational

The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.

NCT ID: NCT04914598 Not yet recruiting - Clinical trials for Malignant Pleural Effusion

A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions

Start date: May 31, 2021
Phase: Phase 3
Study type: Interventional

Malignant Pleural Effusion or Ascites is a common complication of malignant tumor, The objective of this study is to compare the efficacy of Endostar/cisplatin with placebo/cisplatin in patients with malignant pleural effusion or ascites.

NCT ID: NCT04131231 Not yet recruiting - Breast Cancer Clinical Trials

Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural Effusion

Start date: October 15, 2019
Phase: N/A
Study type: Interventional

This is a prospective, open-label , multicenter randomized controlled trial, with 248 cases in 50 centers planned for a period of 2 years. The aim of the study is to evaluate the safety and effectiveness of microparticles packaging chemotherapeutic drugs (MPCD) therapy on the treatment of malignant pleural effusion (MPE) in patients with advanced lung cancer or breast cancer.

NCT ID: NCT03736122 Not yet recruiting - Clinical trials for Malignant Pleural Effusion

A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites

Start date: January 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Malignant pleural effusion and/ or malignant ascites is generally defined by presence of malignant cells in the effusion fluid. The first-line therapies are mostly intrusive, medically demanding and inefficient, and therefore, it is important to study and develop new therapeutic option to address the unmet need. This protocol for BSG-001 is developed for the treatment of malignant pleural effusion and/ or malignant ascites. BSG-001 is an immune-modulator primarily exerts its effect via Toll-like receptor. The purpose of this study is to assess the safety and tolerability of BSG-001. All eligible subjects will receive BSG-001 for at least 12 weeks (3 cycles).

NCT ID: NCT02429726 Not yet recruiting - Clinical trials for Malignant Pleural Effusion

Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural Effusion

Start date: June 2015
Phase: Phase 2
Study type: Interventional

Objective of this study is to investigate of efficacy and safety of recombinant adenoviral human p53 Gene (rAd-p53) in treatment of malignant pleural effusion, compared to cisplatin. This is a phase 2, double blinded, randomized, active controlled study.